← Back to Screener
Lixte Biotechnology Holdings, Inc. Common Stock (LIXT)
Price$7.00
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)56.01%
Price vs S&P 500 (4W)35.67%
VGM Score89.30
Market Capitalization$86.68M
All Metrics
Book Value / Share (Quarterly)$0.68
P/TBV (Annual)1.30x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.37
Price vs S&P 500 (YTD)69.96%
EPS (TTM)$-1.10
10-Day Avg Trading Volume0.24M
EPS Excl Extra (TTM)$-1.10
EPS (Annual)$-1.24
ROI (Annual)-62.18%
Cash / Share (Quarterly)$0.28
ROA (Last FY)-47.19%
EBITD / Share (TTM)$-0.92
ROE (5Y Avg)-177.11%
Cash Flow / Share (Annual)$-0.35
P/B Ratio10.91x
P/B Ratio (Quarterly)4.49x
Net Income / Employee (Annual)$-2,003,200
Net Interest Coverage (TTM)-5.64x
ROA (TTM)-95.61%
EPS Incl Extra (Annual)$-1.24
Current Ratio (Annual)3.88x
Quick Ratio (Quarterly)2.65x
3-Month Avg Trading Volume0.08M
52-Week Price Return407.25%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.62
P/S Ratio (Annual)433.40x
Asset Turnover (Annual)0.33x
52-Week High$7.50
EPS Excl Extra (Annual)$-1.24
Tangible BV CAGR (5Y)39.01%
26-Week Price Return63.93%
Quick Ratio (Annual)3.83x
13-Week Price Return162.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.78x
Enterprise Value$83.43M
Book Value / Share Growth (5Y)-22.92%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1425.00%
Cash / Share (Annual)$0.58
3-Month Return Std Dev117.60%
Net Income / Employee (TTM)$-2,407,900
ROE (Last FY)-62.18%
Net Interest Coverage (Annual)-4.85x
EPS Basic Excl Extra (Annual)$-1.24
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.10
ROI (TTM)-124.69%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.10
Price vs S&P 500 (52W)382.88%
Year-to-Date Return78.12%
5-Day Price Return-2.91%
EPS Normalized (Annual)$-1.24
ROA (5Y Avg)-144.80%
Net Profit Margin (Annual)-1425.00%
Month-to-Date Return12.00%
EBITD / Share (Annual)$-1.06
Operating Margin (Annual)-1325.00%
ROI (5Y Avg)-177.11%
EPS Basic Excl Extra (TTM)$-1.10
P/TBV (Quarterly)2.49x
P/B Ratio (Annual)3.25x
Book Value / Share (Annual)$1.10
Price vs S&P 500 (13W)153.92%
Beta1.30x
Revenue / Share (TTM)$0.00
ROE (TTM)-124.69%
52-Week Low$0.64
mGradeA
vgmGradeA
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LIXTLixte Biotechnology Holdings, Inc. Common Stock | — | — | A | $7.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Lixte Biotechnology Holdings develops Protein Phosphatase 2A (PP2A) inhibitors designed to enhance combination cancer therapies. The company's lead candidate, LB-100, has demonstrated clinical anti-cancer activity with low toxicity and is intended to work alongside chemotherapy, radiation, and immune checkpoint inhibitors. Lixte is advancing LB-100 through clinical development across multiple cancer indications.